AZN Analysis & News - AstraZeneca PLC | Seeking Alpha

AZN

AstraZeneca PLC | NYSE

1d 5d 1m 6m 1y 5y 10Y MAX Advanced Chart

52wk high:43.30

52wk low:34.38

EPS (FWD):1.92

PE (FWD):20.16

Div Rate (TTM):1.40

Yield (TTM):3.61%

Market Cap:$99.14B

Volume:

Analysis

Upcoming Disappointment In AstraZeneca
Alexander Johansson•Sat, Mar. 2•9 Comments
Has AstraZeneca Returned To Growth?
Chestnut Asset Management•Tue, Feb. 19•3 Comments
AstraZeneca Looks To Expand Lynparza Label Into Additional Market
Terry Chrisomalis•Dec. 26, 2018•5 Comments
Cancer Research Highlight: AstraZeneca Parlays Impressive Results Into A Lightning-Quick Approval
Zach Hartman•Dec. 21, 2018•13 Comments
Cancer Research Highlight: AstraZeneca's Checkpoint Combo Fails To Help In Head And Neck
Zach Hartman•Dec. 11, 2018•9 Comments
Cancer Research Highlight: AstraZeneca Finally Fulfills The Premonitions Of Ill Fate In NSCLC
Zach Hartman•Nov. 18, 2018•4 Comments
Cancer Research Highlight: PARP Inhibition Sets A New Benchmark For Ovarian Cancer
Zach Hartman•Oct. 24, 2018•10 Comments
AstraZeneca Lynparza Scores A Big Win At ESMO
Terry Chrisomalis•Oct. 23, 2018•12 Comments
AstraZeneca Receives FDA Approval For Rare B-Cell Lymphoma Drug Lumoxiti
Terry Chrisomalis•Sep. 18, 2018
AstraZeneca Looks To Its Asthma Drug For Blockbuster Potential
Terry Chrisomalis•Sep. 10, 2018
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany
Avisol Capital Partners•Sep. 3, 2018•2 Comments
How The Diabetes Market May Soon Cross Over Into Parkinson's
Christiana Friedman•Jul. 30, 2018•9 Comments
AstraZeneca's Late-Stage Study Win Reinforces Its Hold On Particular Segment Of Lung Cancer Market
Terry Chrisomalis•May 29, 2018•1 Comment
AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
Terry Chrisomalis•May 14, 2018•2 Comments
How Will This Unexpected War For First-Line Lung End?
Zach Hartman•Apr. 16, 2018•14 Comments

News

Drugmaker selloff intensifies on D.C. pricing headwinds
SA News•Wed, Apr. 17•220 Comments
European Commission OKs new use of AstraZeneca's Lynparza
SA News•Wed, Apr. 10•1 Comment
PhaseBio nabs accelerated review status in U.S. for PB2452; shares up 17% after hours
SA News•Mon, Apr. 8•3 Comments
Inovio earns third milestone from AstraZeneca
SA News•Mon, Apr. 8•5 Comments
Myriad expands partnership with AstraZeneca and Merck
SA News•Thu, Apr. 4•5 Comments
AstraZeneca's Fasenra successful in mid-stage HES study
SA News•Thu, Apr. 4
Iovance Bio up 6% on pipeline update
SA News•Wed, Apr. 3
FDA grants Breakthrough Therapy Designation for Selumetinib in NF1
SA News•Mon, Apr. 1•1 Comment
AstraZeneca down 6% on $3.5B capital raise
SA News•Fri, Mar. 29
AstraZeneca, Daiichi Sankyo ink $6.9B cancer deal
SA News•Fri, Mar. 29•1 Comment
Amarin up 3% on addition of Vascepa to SOC guidelines for diabetes-related CV risk
SA News•Wed, Mar. 27•104 Comments
AVEO up 19% on M&A speculation
SA News•Wed, Mar. 27•26 Comments
Trump reaches across the aisle on drug prices
SA News•Tue, Mar. 26•265 Comments
Ichor Medical inks deal with Astrazeneca to develop DNA-based monoclonal antibody platform
SA News•Tue, Mar. 26•1 Comment
Inovio +5% as Cantor signs on as new bull
SA News•Mon, Mar. 25•16 Comments

More From Our Partners

AstraZeneca is Oversold
at Nasdaq.com (Mon, 11:40AM)
AstraZeneca is Oversold
at Nasdaq.com (Mon, 11:40AM)
AstraZeneca Breaks Below 200-Day Moving Average - Notable for AZN
at Nasdaq.com (Wed, 4:07PM)
AstraZeneca Breaks Below 200-Day Moving Average - Notable for AZN
at Nasdaq.com (Wed, 4:07PM)
AstraZeneca’s Oncology Portfolio: Growth Trends in 2019
at MarketRealist.com (Apr 15, 2019)